Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹1,430Cr
Rev Gr TTM
Revenue Growth TTM
31.96%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

KMCSHIL
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 26.0 | 16.5 | 6.9 | 22.7 | 9.3 | 29.9 | 32.9 | 24.9 | 35.7 | 25.4 | 33.2 | 33.7 |
| 30 | 31 | 31 | 35 | 33 | 40 | 44 | 45 | 46 | 50 | 54 | 57 |
Operating Profit Operating ProfitCr |
| 27.4 | 24.7 | 26.3 | 29.3 | 26.3 | 24.4 | 22.3 | 26.1 | 25.3 | 24.7 | 27.8 | 30.2 |
Other Income Other IncomeCr | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 2 | 2 | 2 | 2 | 2 |
Depreciation DepreciationCr | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
| 10 | 9 | 9 | 12 | 9 | 7 | 5 | 10 | 9 | 10 | 15 | 18 |
| 2 | 2 | 2 | 3 | 2 | 2 | 1 | 3 | 4 | 2 | 4 | 5 |
|
Growth YoY PAT Growth YoY% | 70.4 | 13.6 | -2.0 | 50.4 | -2.3 | -20.6 | -43.5 | -20.9 | -36.3 | 36.8 | 179.4 | 82.8 |
| 17.7 | 17.0 | 16.2 | 19.3 | 15.8 | 10.4 | 6.9 | 12.2 | 7.4 | 11.3 | 14.5 | 16.7 |
| 0.5 | 0.4 | 0.4 | 0.6 | 0.4 | 0.3 | 0.2 | 0.5 | 0.3 | 0.5 | 0.7 | 0.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 13.8 | 17.3 | 28.8 | 28.9 | 16.4 | 16.9 | 6.7 | 32.6 | 14.5 | 13.8 | 30.7 | 22.8 |
| 31 | 35 | 43 | 57 | 66 | 75 | 79 | 99 | 114 | 130 | 175 | 207 |
Operating Profit Operating ProfitCr |
| 15.5 | 18.6 | 22.4 | 20.0 | 19.4 | 21.9 | 22.6 | 27.3 | 26.5 | 26.8 | 24.6 | 27.2 |
Other Income Other IncomeCr | 0 | 1 | 0 | 0 | 2 | 1 | 2 | 2 | 3 | 4 | 3 | 4 |
Interest Expense Interest ExpenseCr | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 |
Depreciation DepreciationCr | 4 | 3 | 3 | 4 | 4 | 5 | 6 | 7 | 8 | 9 | 19 | 21 |
| 0 | 4 | 8 | 10 | 12 | 17 | 18 | 32 | 36 | 41 | 32 | 52 |
| 0 | 1 | 3 | 3 | 4 | 5 | 5 | 8 | 9 | 10 | 10 | 15 |
|
| 141.9 | 2,493.8 | 66.6 | 24.2 | 29.4 | 36.4 | 8.8 | 85.7 | 12.5 | 13.8 | -29.5 | 71.0 |
| 0.3 | 7.5 | 9.8 | 9.4 | 10.5 | 12.2 | 12.4 | 17.4 | 17.1 | 17.1 | 9.3 | 12.9 |
| 0.0 | 0.2 | 0.3 | 0.4 | 0.5 | 0.7 | 0.8 | 1.4 | 1.6 | 1.9 | 1.3 | 2.2 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| -6 | -3 | 8 | 14 | 23 | 34 | 47 | 70 | 97 | 127 | 148 | 166 |
Current Liabilities Current LiabilitiesCr | 9 | 10 | 10 | 12 | 12 | 12 | 13 | 20 | 23 | 46 | 38 | 37 |
Non Current Liabilities Non Current LiabilitiesCr | 12 | 6 | 4 | 11 | 8 | 7 | 29 | 22 | 46 | 74 | 84 | 81 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 3 | 3 | 4 | 8 | 13 | 18 | 26 | 42 | 52 | 34 | 33 | 50 |
Non Current Assets Non Current AssetsCr | 28 | 27 | 34 | 45 | 47 | 52 | 79 | 86 | 130 | 230 | 253 | 250 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 5 | 6 | 10 | 12 | 16 | 11 | 26 | 29 | 32 | 38 | 58 |
Investing Cash Flow Investing Cash FlowCr | -1 | -1 | -4 | -19 | -9 | -8 | -43 | -29 | -48 | -56 | -51 |
Financing Cash Flow Financing Cash FlowCr | -5 | -5 | -5 | 6 | -5 | -4 | 18 | -1 | 16 | 21 | -2 |
|
Free Cash Flow Free Cash FlowCr | 5 | 5 | 6 | -3 | 13 | 7 | -15 | 16 | -12 | -37 | -6 |
| 4,381.6 | 178.4 | 187.8 | 186.5 | 183.9 | 91.1 | 200.3 | 122.7 | 121.1 | 126.5 | 268.7 |
CFO To EBITDA CFO To EBITDA% | 96.4 | 72.5 | 81.7 | 87.8 | 99.0 | 50.7 | 110.2 | 78.3 | 78.2 | 81.1 | 101.2 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 46 | 129 | 212 | 293 | 252 | 204 | 356 | 908 | 938 | 1,324 | 1,001 |
Price To Earnings Price To Earnings | 285.0 | 39.4 | 39.4 | 43.8 | 29.1 | 17.4 | 27.9 | 38.4 | 35.1 | 43.6 | 46.9 |
Price To Sales Price To Sales | 1.3 | 3.0 | 3.9 | 4.1 | 3.1 | 2.1 | 3.5 | 6.7 | 6.0 | 7.5 | 4.3 |
Price To Book Price To Book | 4.6 | 9.6 | 8.8 | 9.7 | 6.4 | 4.0 | 5.6 | 10.5 | 8.3 | 9.2 | 6.1 |
| 10.1 | 17.1 | 17.5 | 21.3 | 15.8 | 9.5 | 15.8 | 24.3 | 23.0 | 29.2 | 19.0 |
Profitability Ratios Profitability Ratios |
| 82.4 | 83.5 | 83.9 | 85.2 | 85.5 | 85.7 | 84.1 | 84.9 | 85.3 | 86.2 | 85.5 |
| 15.5 | 18.6 | 22.4 | 20.0 | 19.4 | 21.9 | 22.6 | 27.3 | 26.5 | 26.8 | 24.6 |
| 0.3 | 7.5 | 9.8 | 9.4 | 10.5 | 12.2 | 12.4 | 17.4 | 17.1 | 17.1 | 9.3 |
| 9.9 | 27.1 | 33.6 | 25.4 | 28.8 | 30.6 | 20.6 | 28.4 | 22.5 | 18.5 | 16.2 |
| 1.2 | 24.0 | 22.3 | 21.9 | 22.0 | 23.2 | 20.2 | 27.3 | 23.5 | 21.2 | 13.0 |
| 0.4 | 10.9 | 14.1 | 12.6 | 14.5 | 16.8 | 12.2 | 18.4 | 14.7 | 11.5 | 7.5 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
KMC Speciality Hospitals (India) Limited, a subsidiary of **Sri Kauvery Medical Care (India) Limited** (which holds a **75%** stake), is a premier tertiary healthcare provider headquartered in Trichy, Tamil Nadu. Operating under the renowned **Kauvery Hospital** brand, the company specializes in high-end multi-specialty services, organ transplants, and advanced mother and child care.
---
### **Strategic Infrastructure and Capacity Expansion**
The company has aggressively expanded its footprint in the Trichy region, transitioning from a single-unit hospital to a dual-facility powerhouse with a combined capacity of **450 beds**.
| Facility | Focus Area | Capacity | Status |
| :--- | :--- | :--- | :--- |
| **Legacy Block** (Main Unit) | Multi-Specialty Tertiary Care | **250 Beds** | Operational (G+6F+1B) |
| **Maa Kauvery** (New Unit) | Mother & Child; Paediatric Super Specialties | **200 Beds** | Operational since **Jan 29, 2024** |
**Maa Kauvery Unit Highlights:**
* **Specialized Intensive Care:** Features a **50-bedded** Neonatal Intensive Care Unit (**NICU**), a **16-bedded** Paediatric Intensive Care Unit (**PICU**), and an **11-bedded** Paediatric Emergency Department.
* **Transplant Excellence:** Includes a dedicated **5-bedded** unit for Bone Marrow, Liver, and Renal transplants.
* **Diagnostic Suite:** Equipped with **CT, MRI, Mammogram, Dexa Scan**, and advanced **OT Theatres** (including Labour OT).
---
### **Operational Model and Regional Dominance**
The company operates in a single segment—**Medical and Healthcare Services**—with a dominant market share in Central Tamil Nadu.
* **Catchment Area:** Approximately **92%** of In-patients are drawn from **9 key districts**, with a service radius extending over **200 kilometers**.
* **Patient Volume (FY24):** Recorded **14,194** In-patient and **1,24,318** Out-patient visits.
* **Occupancy Levels:** Maintained a high average occupancy rate of **over 90%** (FY24).
* **Strategic Outsourcing:** To optimize specialized care, cardiac procedures for government-empanelled patients are outsourced to **Kauvery Heart City Hospital** (a division of the holding company) located on the same premises.
* **Human Capital:** Supported by a workforce of **1700+** employees and associates, including **170 Doctors**.
**IP Volume Distribution by District:**
* **Tiruchirapalli:** **50%**
* **Pudukkottai & Thanjavur:** **9% each**
* **Ariyalur & Perambalur:** **9% combined**
* **Other Districts (Karur, Cuddalore, etc.):** **15%**
---
### **Digital Transformation and Clinical Integration**
KMC leverages a "Digital First" approach to enhance patient safety and operational throughput.
* **Clinical Automation:** Implementation of **Electronic Medical Records (EMR)** and **Electronic Prescriptions** to eliminate medication errors.
* **Connected ICU:** A digital platform utilizing advanced sensors for **real-time monitoring** and immediate clinical intervention.
* **Proprietary CRM (CHARM):** A unified initiative that integrates all patient interactions into a single platform for personalized communication.
* **Administrative Efficiency:** Deployment of **Robotic Process Automation (RPA)**, including an automated **GRN system** processing **4,300 documents monthly**.
---
### **Financial Performance and Credit Profile**
The company has demonstrated a robust growth trajectory, characterized by a **10-year Revenue CAGR of 17.8%** and a **10-year PBT CAGR of 38.6%**.
**Key Financial Metrics:**
| Metric (INR Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 |
| :--- | :--- | :--- | :--- |
| **Total Income** | **23,468.40** | **18,073.52** | **15,576.00** |
| **EBITDA** | **5,997.18** | **5,094.57** | **4,450.23** |
| **Networth** | **19,570.00** (Q3'26) | **14,357.97** | **11,350.21** |
| **Debt-Equity Ratio** | - | **0.35** | **0.39** |
**Recent Quarterly Highlights (Q3 FY'26):**
* **Revenue Growth:** **33%** YoY increase.
* **Margin Expansion:** EBITDA Margin improved to **31%** (up from **27%**); PAT Margin rose to **16.5%**.
* **Liquidity:** Cash and fixed deposits stood at **INR 49.0 Cr** as of Dec 2025.
**Credit Rating Upgrade (March 2026):**
**India Ratings and Research (Ind-Ra)** upgraded the long-term rating to **IND AA- / Stable** (from IND A+), citing a strengthening financial profile and successful scaling of the Maa Kauvery unit.
---
### **Sustainability and ESG Framework**
KMC is transitioning toward a green energy model to mitigate rising utility costs and environmental impact.
* **Energy Transition:** Currently sources **78%** of energy from renewable sources (Solar/Wind).
* **Strategic Investment:** Acquired a **26% stake** in **Gardenia Energy Private Limited** (Sept 2025) to secure solar power.
* **Target:** Aiming for **100% renewable energy usage** by the end of **FY 2026-27**.
* **Resource Efficiency:** 100% LED lighting, **BLDC fans** (60% power reduction), and **Variable Frequency Drives (VFD)** for HVAC systems.
* **Waste Management:** Discontinued **one-time plastics**; hazardous and bio-medical waste are managed via government-approved vendors.
---
### **Academic and Talent Strategy**
To counter the industry-wide scarcity of skilled medical resources, the company has pivoted toward an academic-led growth model.
* **Medical Education:** Increased academic capacity from **20+** seats in 2024 to over **44 DnB and Diploma seats** by late 2025.
* **Quality Standards:** **NABH accredited** and a pioneer in adopting the **5S Workplace Organization Method** in the Indian healthcare sector.
---
### **Risk Management and Governance**
The company maintains a rigorous risk mitigation framework overseen by a dedicated committee.
**Legal and Regulatory Exposures:**
* **Supreme Court Compliance:** Remitted **Rs. 7.01 Cr** in Sept 2024 to settle a long-standing property auction litigation (V.S. Palanivel Case).
* **Minimum Wage Litigation:** Currently protected by an **interim stay** against a Tamil Nadu government notification revising hospital wages; the final outcome remains a potential financial sensitivity.
* **Corporate Guarantees:** Provides guarantees for its holding company up to **Rs. 98.57 Crs** (capped at **60% of Tangible Net Worth**).
**Operational Risks:**
* **Manpower Attrition:** High competition for specialized clinical talent.
* **Cybersecurity:** Reported **Nil** data breaches for FY24/25; currently streamlining shareholder e-voting via a **single login credential** system through NSDL/CDSL.
* **Safety:** Conducts fire drills **twice a year** and regular amenity risk audits to manage high-pressure systems like **O2 cylinders**.